Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Biomedicines , 10 (11), 2696
A 2025 Phase I trial (Lee & Burgess, 2025) demonstrated that IV BPC-157 doses up to 20 mg were tolerated in healthy volunteers with no serious adverse events
For UK medicines regulation, refer to the MHRA.
After an initial loading phase of six injections over two weeks (or more frequently if neurological symptoms are present), maintenance injections are given every two to three months for life to prevent deficiency recurrence
US$ 27.10
US$ 27.73
US$ 25.13
US$ 29.82
US$ 29.46
US$ 23.19
